USCB Stock USCB Financial Holdings (USCB, $23.13) RSI Indicator left the overbought zone on September 08, 2026
at Tickeron.com
This is a signal that USCB's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options. A.I.dvisor looked back and found 28 similar cases where USCB's RSI Indicator left the overbought zone, and in of them led to a successful outcome. Odds of Success:
USCB sees MACD Histogram just turned negative
USCB saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on September 14, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 48 instances where the indicator turned negative. In 32 of the 48 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 67%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on USCB as a result. In 72 of 111 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 65%.
USCB moved below its 50-day moving average on September 29, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where USCB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 63%.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where USCB's RSI Indicator exited the oversold zone, 15 of 21 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 71%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +1.27% 3-day Advance, the price is estimated to grow further. Considering data from situations where USCB advanced for three days, in 194 of 270 cases, the price rose further within the following month. The odds of a continued upward trend are 72%.
USCB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 127 of 167 cases where USCB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 76%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 21 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 32 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 57, placing this stock better than average.
The Tickeron SMR rating for this company is 42 (best 1 - 100 worst), indicating slightly weaker than average sales and a marginally profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating steady price growth. USCB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 68 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.794) is normal, around the industry mean (1.321). P/E Ratio (14.513) is within average values for comparable stocks, (24.015). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.186). Dividend Yield (0.021) settles around the average of (0.030) among similar stocks. P/S Ratio (4.421) is also within normal values, averaging (3.747).